the Program - Simposio Científico SOGUG
Transcripción
the Program - Simposio Científico SOGUG
V SIMPOSIO CIENTÍFICO SOGUG 5th SCIENTIFIC MEETING SOGUG Madrid 19 al 21 de Noviembre 2014 | 19th to 21st November 2014 Comité Científico | Scientific Committee Dr. Javier Cassinello Dr. Daniel Castellano Dr. Miguel Ángel Climent Dr. Ignacio Durán Dra. Aránzazu González del Alba Organizado por | Organized by Dr. Luis León Dra. Marta López-Brea Dra. Mª José Méndez-Vidal Dr. Juan Fco. Rodríguez-Moreno Sede | Venue Casino de Madrid C/ Alcalá, 15, Madrid Telf.: 91 521 87 00 MIÉRCOLES 19 NOVIEMBRE WEDNESDAY 19th NOVEMBER 18:30 - 20:30 Encuentro con el Profesor | Meeting with the Professor a enfermedad ósea en el cáncer de próstata | Bone disease in L prostate cancer Dr. Dominik Berthold, CHUV, Lausanne, Switzeland Auspiciado por Bayer | Sponsored by Bayer Sede: Casino de Madrid | Venue: Casino de Madrid Plazas limitadas. Se adjudicarán por riguroso orden de inscripción | Limited places. Previous registration is mandatory 20:30 - 21:45 Simposio Satélite - Janssen | Satellite Symposium - Janssen Para asistir contacte con el Patrocinador | To attend, please contact the Sponsor JUEVES 20 NOVIEMBRE THURSDAY 20th NOVEMBER 08:15 - 09:15 Grupo “Young SOGUG” 1 “Young SOGUG” Group 08:15 - 08:30 Presentación del Proyecto “Young SOGUG” Presentation of the “Young SOGUG” Project Dr. Juan Fco. Rodríguez-Moreno, Hospital Madrid Norte Sanchinarro, Madrid 08:30 - 08:40 na carrera de investigación clínica fuera de España: formación en centros de U excelencia en EEUU | A clinical research career abroad: training at centres of excellence in the USA Dr. Carlos Álvarez Fernández, Hospital Central de Asturias, Oviedo 08:40 - 08:55 Primeros pasos en investigación clínica. Becas: ¿cuáles, cuándo y cómo solicitarlas? | First steps in clinical research. Grants: which ones, when and how to apply for Dra. Elena Castro, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid 08:55 - 09:15 Discusión y preguntas | Q&A Dr. Álvaro Montesa, Hospital Universitario Carlos Haya, Málaga 09:30 - 10:25 Inmunoterapia como estrategia de tratamiento en los tumores genitourinarios | Immunotherapy as a strategy of treatment of genitourinary tumours Moderadores | Chairpersons Dr. José Ángel Arranz, Hospital Universitario Gregorio Marañón, Madrid Dr. Francisco Zambrana, Hospital Infanta Sofía, Madrid 09:30 - 09:50 Inmunoterapia para no inmunólogos | Immunotherapy for non-immunologists Dr. Larry Fong, USCF Medical Centre, San Francisco, USA 09:50 - 10:10 Inmunoterapia en tumores urológicos | Immunotherapy in urological tumours Dr. Tom Powles, Barts Cancer Institute, London, UK 10:10 - 10:25 Discusión | Discussion JUEVES 20 NOVIEMBRE THURSDAY 20th NOVEMBER 10:30 - 12:30 Talleres | Workshops 1.Vacunas para el tratamiento de cáncer de próstata | Vaccines for the treatment of prostate cancer Dr. Larry Fong, USCF Medical Centre, San Francisco, USA 2.Inmunoterapia en cáncer renal y futuro de las combinaciones con TKI Immunotherapy in renal cancer and the future of combinations with TKI Dr. José Luis Pérez Gracia, Clínica Universitaria de Navarra, Pamplona 3.Inmunoterapia en cáncer de vejiga. Perspectivas y nuevos horizontes Immunotherapy in bladder cancer. Perspectives and new horizons Dr. Tom Powles, Barts Cancer Institute, London, UK Los tres talleres se realizarán simultáneamente en dos sesiones consecutivas. Plazas limitadas. Se adjudicarán por riguroso orden de inscripción The three workshops will be held simultaneously in two consecutive sessions. Previous registration is mandatory 12:30 - 13:30 Concurso de casos clínicos | Clinical vignettes contest Moderadores | Chairpersons Dr. Javier Cassinello, Hospital General Universitario, Guadalajara Dra. Marta López-Brea, Hospital Marqués de Valdecilla, Santander Dr. Juan Fco. Rodríguez-Moreno, Hospital Madrid Norte Sanchinarro, Madrid 13:30 - 15:15 Simposio de industria - Astellas | Industry workshop - Astellas Para asistir contacte con el Patrocinador | To attend, please contact the Sponsor JUEVES 20 NOVIEMBRE THURSDAY 20th NOVEMBER 15:15 INICIO SESIÓN DE TARDE | START OF AFTERNOON SESSION 15:15 - 16:45 Terapias dirigidas a la vía del AR y el hueso | Therapies targeting the androgen receptor pathway and the bone Moderadores | Chairpersons Dr. Ignacio Durán, Hospital Universitario Virgen del Rocío, Sevilla Dr. Joan Carles, Hospital General Universitari Vall d’Hebron, Barcelona 15:15 - 15:40 ecanismos de progresión en el cáncer de próstata resistente a la castración M Mechanisms for progression of castrate resistant prostate cancer Dr. Enrique González Billalabeitia, Hospital General Universitario Morales Meseguer, Murcia 15:40 - 16:05 El andrógeno y su receptor como diana de tratamiento | The androgen and its receptor as a treatment target Dr. Pablo Maroto, Hospital de la Santa Creu i Sant Pau, Barcelona 16:05 - 16:30 Actualizaciones en tratamientos dirigidos al hueso y combinación con otras estrategias terapéuticas | Update on therapies targeting the bone and combination with other treatment strategies Dr. Álvaro Pinto, Hospital Universitario La Paz, Madrid 16:30 - 16:45 Discusión | Discussion 16:45 - 17:15 Café | Coffee break JUEVES 20 NOVIEMBRE THURSDAY 20th NOVEMBER 17:15 - 19:00 Talleres | Workshops 1. Discusión de 2 casos clínicos | Discussion of 2 clinical vignettes -Tratamiento de secuenciación dirigido sólo al AR | Sequencing treatment aiming only at AR -Mecanismos de resistencia y subgrupo de pacientes sensibles a inhibidores de AR Mechanisms of resistance and subgroup of patients sensible to AR inhibitors Dr. Ignacio Durán, Hospital Universitario Virgen del Rocío, Sevilla 2. Discusión de 2 casos clínicos | Discussion of 2 clinical vignettes -Tratamientos de combinación futura en CPRC | Treatments of future combination in CRPC - Nuevas dianas terapéuticas en CPRC | New therapeutic targets in CRPC Dr. Pablo Maroto, Hospital de la Santa Creu i Sant Pau, Barcelona 3. Discusión de 2 casos clínicos | Discussion of 2 clinical vignettes -Tratamiento dirigido sólo a metástasis óseas | Treatment targeting only bone metastases -Impacto de fármacos dirigidos al hueso en puntos con afectación de partes blandas Impact of drugs targeting the bone with soft tissue parts Dr. Álvaro Pinto, Hospital Universitario La Paz, Madrid Los tres talleres se realizarán simultáneamente en dos sesiones consecutivas Plazas limitadas. Se adjudicarán por riguroso orden de inscripción The three workshops will be held simultaneously in two consecutive sessions. Previous registration is mandatory VIERNES 21 NOVIEMBRE FRIDAY 21st NOVEMBER 08:30 - 09:15 Asamblea General SOGUG | SOGUG General Assembly 09:30 - 11:00 Tratamiento de quimioterapia en tumores GU | Chemotherapy treatment in GU tumours Moderadores | Chairpersons Dra. Begoña Mellado, Hospital Clínic, Barcelona Dra. Aránzazu González del Alba, Hospital Universitari Son Espases, Palma de Mallorca 09:30 - 09:55 La integración de la quimioterapia en el carcinoma de próstata hormono-sensible Integration of chemotherapy in hormone-sensitive prostate carcinoma Dr. Ronald de Wit, Erasmus University Medical Center, Rotterdam, Holland 09:55 - 10:20 L a integración del tratamiento citotóxico en el CPRC | Integration of cytotoxic treatment in CRPC Dr. Miguel Ángel Climent, Instituto Valenciano de Oncología (IVO), Valencia 10:20 - 10:45 E l papel de la quimioterapia en el cáncer de vejiga | The role of chemotherapy in bladder cancer Dr. Joaquim Bellmunt, Dana-Farber, Brigham and Women’s Cancer Centre, Harvard Univ., Boston, USA 10:45 - 11:00 Discusión | Discussion VIERNES 21 NOVIEMBRE FRIDAY 21st NOVEMBER 11:15 - 13:00 Talleres | Workshops 1. Discusión de 2 casos clínicos | Discussion of 2 clinical vignettes -Paciente ideal para tratamiento de QT en el paciente hormono sensible | Ideal patient for chemotherapy treatment in hormone-sensible patient -Paciente ideal para tratamiento de QT en CPRC | Ideal patient for chemotherapy treatment in CRPC Dr. Ronald de Wit, Erasmus University Medical Center, Rotterdam, Holland 2. Discusión de 2 casos clínicos | Discussion of 2 clinical vignettes -Paciente unfit y nuevas propuestas de tratamiento | Unfit patient and new treatment approaches -Paciente tras fallo platino. Impacto de nuevas moléculas | Platinum failure patient. Impact of new molecules Dr. Joaquim Bellmunt, Dana-Farber, Brigham and Women’s Cancer Centre, Harvard Univ., Boston, USA 3. Discusión de 2 casos clínicos | Discussion of 2 clinical vignettes -Paciente TGNS de alto riesgo. Inadecuada respuesta de marcadores tumorales a QT High risk NSGCT patient. Inadequate tumour marker response to chemotherapy -Vigilancia activa en TG. Recomendaciones y normas de seguimiento | Active surveillance in GCT. Recommendations and standards for monitoring Dr. Karim Fizazi, Institute Gustave-Roussy, Villejuif, France Los tres talleres se realizarán simultáneamente en dos sesiones consecutivas. Plazas limitadas. Se adjudicarán por riguroso orden de inscripción The three workshops will be held simultaneously in two consecutive sessions. Previous registration is mandatory VIERNES 21 NOVIEMBRE FRIDAY 21st NOVEMBER 15:30 INICIO SESIÓN DE TARDE | START OF AFTERNOON SESSION 15:30 - 17:00 Estado de la investigación en tumores GU | Ongoing research in GU tumours Moderadores | Chairpersons Dr. Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid Dr. Jesús García-Donas, Centro Integral Oncológico Clara Campal (CIOCC), Madrid 15:30 - 16:00 Mecanismos cell cancer de resistencia en cáncer renal | Mechanisms of resistance in renal Dr. Primo Lara, UC Davis Comprehensive Cancer Center, Sacramento, USA 16:00 - 16:30 ltas dosis de QT en tumores germinales: a qué pacientes y cómo | High dose A chemotherapy in germ cell cancer: to whom and how Dra. Anja Lorch, UKD Universitätsklinikum, Düsseldorf, Germany 16:30 - 17:00 Conferencia anual SOGUG: Tres décadas en la investigación clínica en cáncer renal | SOGUG annual lecture: Three decades in renal cell cancer clinical research Dr. Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid 17:00 - 17:30 Café | Coffee break VIERNES 21 NOVIEMBRE FRIDAY 21st NOVEMBER 17:30 - 18:30 Talleres | Workshops Terapias dirigidas en cáncer renal y retos en la práctica clínica Targeted therapies in renal cancer and challenges in clinical practice 1.Evaluación de la respuesta en el tratamiento con terapias dirigidas Response evaluation when using targeted therapies Dra. Mª José Méndez-Vidal, Hospital Universitario Reina Sofía, Córdoba Dr. Roberto García-Figueiras, Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela 2.Secuenciación en cáncer renal: dos opciones para un mismo problema (TKI-TKI) | Sequencing in renal cancer: two options for the same problem (TKI-TKI) Dr. Javier Puente, Hospital Clínico Universitario San Carlos, Madrid 3. Secuenciación en cáncer renal: dos opciones para un mismo problema (TKI-mTOR) | Sequencing in renal cancer: two options for the same problem (TKI-mTOR) Dr. Viktor Grünwald, Hannover Medical School, Hannover, Germany Talleres simultáneos. Plazas limitadas. Se adjudicarán por riguroso orden de inscripción The three workshops will be held simultaneously. Previous registration is mandatory 18:30 Clausura | Closing remarks Dr. Daniel Castellano, Presidente de SOGUG Participantes Participants Ponentes y Moderadores | Speakers & Chairpersons PARTICIPANTES PARTICIPANTS Dr. Carlos Álvarez Fernández Hospital Central de Asturias, Oviedo FORMACIÓN ACADÉMICA • Diplomatura en Enfermería, Sept 99 - Jun 02. E.U. de Enfermería, Universidad de Oviedo, Asturias. • Licenciatura en Medicina, Sept 02 - Jun 08. Facultad de Medicina, Universidad de Oviedo, Asturias. Examen de Grado de Licenciatura, con calificación de Notable. • Especialista en Oncología Médica, M.I.R. May 09 - May 13. Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias. • Suficiencia investigadora, Jun 12, “Valor predictivo de la expresión de reduced folate carrier (RFC) en el tratamiento del cáncer de pulmón no microcítico (CPNM) avanzado con pemetrexed”. • Máster Universitario en Investigación en Cáncer, Jun 12. Universidad de Oviedo - Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Asturias. • Diploma de Postgrado en Oncología Médica – S.E.O.M., Curso 10 - 12. Universidad de Girona – Sociedad Española de Oncología Médica. EXPERIENCIA LABORAL • Enfermero. Centro Comunitario de Sangre y Tejidos de Asturias. Jun 02 - May 08. • M.I.R. Oncología Médica. Hospital Universitario Central de Asturias. Servicio de Salud del Principado de Asturias (SESPA). May 09 - May 13. (Estancia Formativa en MD Anderson Cancer Center Madrid España. Feb 12) • Oncólogo médico (F.E.A.). Hospital Universitario Central de Asturias. Servicio de Salud del Principado de Asturias (SESPA). Jun 13 - Mar 14. • Oncólogo médico (Visiting Physician). University of California, San Francisco. Helen Diller Family Comprehensive Cancer Center. Department of Hematology /Oncology, Genitourinary Tumors Program. - Beca del grupo SOGUG - Abr 14 - Jun 14. Varias publicaciones como primer firmante y como segundo y siguientes firmantes. Varias comunicaciones en Congresos como primer firmante y como segundo y siguientes firmantes. MIEMBRO DE COMISIONES Y SOCIEDADES CIENTÍFICAS Comisión de Docencia (Julio 2011 - Mayo 2013. H.U.C.A). Comisión de Tumores (Ene 12 - May13. H.U.C.A.). Grupo Español de Oncología Genitourinaria (S.O.G.U.G.). Sociedad Española de Oncología Médica (S.E.O.M.). European Society for Medical Oncology (E.S.M.O.). American Society of Clinical Oncology (A.S.C.O.) OTROS MÉRITOS Colaborador de Honor del Departamento de Medicina de la Universidad de Oviedo. Cursos 2011/12, 2012/13 y 2013/14. PARTICIPANTES PARTICIPANTS Dr. José Ángel Arranz Hospital Universitario Gregorio Marañón, Madrid - Licenciado en Medicina y Cirugía (Universidad de Valladolid, 1985). - Especialista en Oncología Médica (Hospital General Universitario Gregorio Marañón, 1990). -Miembro del Comité de Expertos en Tumores Urológicos de la Consejería de Salud de la Comunidad Autónoma de Madrid (1993). - Diplomatura en Informática y Estadística (Universidad Autónoma de Barcelona, 1994). -Jefe de Sección del Servicio de Oncología Médica del Hospital General Universitario Gregorio Marañón (desde 2007 hasta la actualidad), y responsable de la “Unidad de Tumores Urológicos y Ginecológicos” en dicho centro. Dr. Joaquim Bellmunt Dana-Farber, Brigham and Women’s Cancer Centre, Harvard Univ., Boston, USA Dr. Joaquim Bellmunt is Associate Professor of Medicine at Harvard Medical School and Attending Physician of Solid Tumor Oncology at Dana-Farber Cancer Institute (DFCI). He also serves as the Director of the Bladder Cancer Center at DFCI and Dana-Farber/Brigham and Women’s Cancer Center, Harvard University, Boston working as part of a multidisciplinary team to provide complete care for patients with genitourinary malignancies. He is past chairman of the Committee of Advanced Bladder Cancer in the European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group (EORTC-GU). He is co-founder and has been President of the Spanish Group for Treatment of Genitourinary Tumors (SOGUG). Dr. Bellmunt’s efforts have largely centered on improving the care of patients with genitourinary malignancies focusing on bladder and renal cell carcinoma. His areas of interest in genitourinary oncology include the development of drugs directed to novel therapeutic targets and early clinical and translational research in the field of growth factor receptors and angiogenesis. While his research interests are focused on bladder cancer, he has extensive experience treating prostate, penile and kidney cancer. He serves on International committees focused on improving the treatments of genitourinary and bladder cancers. He is a member of the Editorial Board of the Journal of Clinical Oncology and European Urology. He has been chairing two of the larger multicenter international trials of new drugs in the treatment of bladder cancer, in one of them, leading to the establishment of a new drug for bladder cancer patients. Dr. Bellmunt’s research focuses on clinical trials with aims to improve the treatment of patients with advanced bladder (urothelial) tumors as well as the development of novel agents for this disease. Dr. Bellmunt is currently involved in collaborative efforts with basic scientists to analyze clinical, tissue, and biomarkers to optimize the administration of targeted therapeutic agents in bladder cancer. PARTICIPANTES PARTICIPANTS Dr. Dominik Berthold CHUV, Lausanne, Switzeland He obtained his MD at the University of Bologna/Italy in 1998 with a thesis on therapeutic cancer vaccine employing genetically engineered breast cancer cells. He did this specialty training in internal medicine and medical oncology in southern Switzerland (F. Cavalli). During his fellowship from 2005-2007 at Princess Margaret Hospital (PMH) in Toronto, Canada, (mentor Dr. IF Tannock, MM Moore) he focused his clinical and research activity on genito-urinary cancers and particularly on prostate cancer. Dr. Berthold currently heads a specialized prostate clinic at the University Hospital in Lausanne, Switzerland, based on high quality multidisciplinary care as well as clinical research. He is the medical responsible of the clinical trial unit, a member of the ethic committee as well as a member of several professional societies (ASCO, ESMO, ESO) and research networks in Switzerland and in Europe (SAKK, EORTC). He is strongly committed to high quality care in oncology as well as to rigorous research in genito-urinary cancer. Dr. Joan Carles Hospital General Universitari Vall d’Hebron, Barcelona El Dr. Joan Carles es licenciado en Medicina y Cirugía por la Universidad Autónoma de Barcelona (1987), obteniendo su doctorado en 1992. Completó su formación en la especialidad de Oncología Médica en el Hospital Universitario Germans Trias i Pujol de Badalona y en 1996 recibió el Certificado Europeo en Oncología Médica de Viena. En 1991 se incorporó a la Unidad de Oncología Médica del Hospital de Terrassa y desde abril 1992 hasta septiembre 2008 trabajó como médico oncólogo en el Hospital del Mar de Barcelona. En septiembre de 2008 se incorporó al Departamento de Oncología de Vall d’Hebron como Jefe de la unidad de Genitourinario, sistema nervioso central, sarcoma y tumores de origen desconocido. El Dr. Joan Carles es co-fundador y ex-vicepresidente de la Sociedad Española para el Tratamiento de Cáncer Genitourinario (SOGUG), miembro de la Sociedad Española de Tumores de Cabeza y Cuello (CTT), así como miembro del Grupo Español de Investigación en Sarcoma (GEIS). Es profesor de Medicina en la Universidad Autónoma de Barcelona desde 1995 y coordinador del programa de formación de Oncología Médica. El Dr. Carles ha sido autor de alrededor de más de 70 artículos y más de 100 presentaciones en congresos y capítulos de libros. Sus intereses de investigación son la oncología clínica genitourinaria, el sarcoma y principios de la investigación traslacional y clínica de los polimorfismos genéticos, así como la angiogénesis, como objetivos en la terapia del cáncer. También coordina los ensayos clínicos multicéntricos nacionales de los nuevos medicamentos en el tratamiento de la próstata, el riñón y el cáncer de vejiga. Además, el Dr. Carles es un miembro de la Sociedad Americana de Oncología Clínica (ASCO), miembro de la Sociedad Europea de Oncología Médica (ESMO) y miembro de la Asociación Española de Oncología Médica (SEOM). Ha actuado como consultor en calidad de asesor para la preparación y el desarrollo de las Directrices de Oncología para el gobierno de Catalunya (Oncoguies CatSalut). PARTICIPANTES PARTICIPANTS Dr. Javier Cassinello Espinosa Hospital General Universitario, Guadalajara - Licenciado en Cirugía y Medicina por la Universidad Complutense de Madrid. - Grado de Licenciado y realización de 12 cursos de Doctorado por la Universidad Complutense de Madrid y por la Universidad de Alcalá de Henares. - Especialista en Oncología Médica. Residencia (MIR) efectuada en el Hospital 12 de Octubre de Madrid en el Servicio de Oncología Médica -periodo 1986-1990-. - Médico Adjunto de Oncología Médica en la Unidad de Oncología Médica del Hospital Miguel Servet de Zaragoza -periodo 1992-1995-. - Jefe de la Unidad de Oncología Médica del Hospital General Universitario de Guadalajara, desde 1995 hasta la actualidad. - Estancia como becado en el Dpto. de Ginecología / Medicina Interna del Hospital de Oulu (Finlandia) en 1978. - Beca SEOM: “Clinical Exchange Program”. UTM Anderson Cancer Center, Houston (Texas), EEUU en 1992. Experiencia en Investigación Clínica de 18 años. Miembro de la Sociedad Española de Oncología Médica (SEOM), de la European Society of Medical Oncology (ESMO) y de la American Society of Clinical Oncology (ASCO). Dr. Daniel Castellano Hospital Universitario 12 de Octubre, Madrid Dr. Castellano is a Medical Oncologist of University Hospital 12 de Octubre (Madrid) with a special interest in the diagnosis and treatment of genitourinary tumors such as renal, bladder, prostate and testicular cancer. He is currently Head of the GU Oncology Unit, Germ Cell Tumors Unit and Neuroendocrine Tumors Unit. His research is focused on the development of new drugs in GU tumors and Neuroendocrine tumors, and he is the Principal Investigator of more than 15 clinical trials (phase I, II and III trials). He has published more than 30 peer-review articles in relevant and recognized oncology journals. Dr. Castellano is Chair of Spanish Oncology Genitourinary Group (SOGUG), member of executive committee of GETNE (Spanish Group of Neuroendocrine tumors), and member of a different International and National Scientific organizations. PARTICIPANTES PARTICIPANTS Dra. Elena Castro Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid Dr. Elena Castro received her MD from Universidad de Salamanca in 2003 and her PhD in 2010. She specialized in Medical Oncology at Hospital Uiversitario de Salmanca. After completing her residency training, she moved to London where she worked for four years as clinical research fellow in cancer genetics and prostate cancer at the Insitute of Cancer Research & The Royal Marsden Hospital. Dr. Castro moved back to Spain in January 2013 to the Prostate Cancer Unit at the Spanish National Cancer Research Centre (CNIO). Her research is focused on populations with high risk of prostate cancer and on the clinical and molecular characterization of prostate cancer tumors with DNA repair defects. She also works as honorary consultant in Prostate Cancer at Centro Oncológico Integral Clara Campal. Dr. Ignacio Durán Hospital Universitario Virgen del Rocío, Sevilla El Dr. Ignacio Durán trabaja en el Servicio de Oncología Médica del Hospital Universitario Virgen del Rocío de Sevilla. Fue coordinador de docencia y del programa de tumores genitourinarios del centro Integral Oncológico “Clara Campal” del Grupo Hospital de Madrid. Licenciado en Medicina y Cirugía por la Universidad de Salamanca y Doctor por la Universidad Complutense de Madrid. A lo largo de su carrera ha desarrollado estancias formativas en distintos centros investigadores nacionales e internacionales tales como la sede del CSIC de la Universidad de Salamanca, la Universidad Católica del Sacro Cuore de Roma (Italia), el “Centre Hospitalier Universitaire” de Nantes (Francia) y el “Memorial Sloan Kettering Cancer Center” de Nueva York (EE.UU).Tras su formación clínica en el Hospital Clínico Universitario de Son Dureta (Palma de Mallorca), trabajó en el Servicio de Oncología Médica del Hospital Universitario Doce de Octubre (Madrid) y durante el trienio 2004-2007 en los departamentos de Desarrollo de Nuevos Fármacos y de Tumores Genitourinarios del “Princess Margaret Hospital” de Toronto (Ontario, Canadá). Durante su estancia en Toronto completó un programa de Máster de docencia orientada a la medicina en la Universidad de Toronto. Es autor de importantes trabajos en diferentes ámbitos de la oncología médica publicados en destacadas revistas científicas. A lo largo de su carrera ha recibido entre otros galardones, el ASCO Foundation Merit Award, el Novartis Young Canadian Investigator Award y el University Health Network Outstanding Research Presentation Award. PARTICIPANTES PARTICIPANTS Dr. Karim Fizazi Institute Gustave-Roussy, Villejuif, France HOSPITAL AND LABORATORY APPOINTMENTS September 2009: Full Professor, Institut Gustave Roussy, University of Paris, France. Since June 2005: Appointed Head of the Department of Medicine, Institut Gustave Roussy (IGR), France. Since 2004: Chairman of the Genito-urinary Oncology Group, Institut Gustave Roussy (IGR), France. Since 2001: Assistant Professor in Medical Oncology, Department of Medicine, Institut Gustave Roussy (IGR), France. 1999-2001: Visiting Assistant Professor, Genitourinary Medical Oncology Department, MD Anderson cancer Center, Houston, TX, USA. 1997-1999: Assistant Professor in Medical Oncology, department of Medicine, Institut Gustave Roussy (IGR), France. 1995-1997: Appointed Chef de clinique (Fellow) Medical oncology, Institut Gustave Roussy (IGR), France. 1991-1995: Appointed Interne des hôpitaux de Paris (Residency): - Medical Oncology, Department of Pr Marty, Hôpital St Louis (1995) - Medical Oncology, Department of Pr Droz and Dr Le Chevalier, IGR (1995) - Medical Oncology, Department of Pr Pouillart, Institut Curie (1993) - Medical Oncology, Department of Pr Tursz, IGR (1993) - Radiotherapy, Department of Pr Cosset, Institut Curie (1992) - Medical Oncology, Department of Dr Ruffié, IGR (1992) - Cardiology, Department of Pr Leca, Hôpital Laënnec (1991) - Emergency, Department of Dr Duliouste, La Rochelle (1991) 1994: Diplôme d’Etudes Appliquées: Postgraduate Diploma prior to PhD, Fundamental Bases of Oncogenesis, Pr Tursz’ Laboratory, IGR MEDICAL AND SCIENTIFIC QUALIFICATIONS 2003: Ph.D. (Molecular Oncology) 1997: « Ancien Chef de Clinique » (Fellowship), Medical Oncology 1995: MD (Medical Oncology) 1990: Concours de l’Internat de Paris (Competitive Examination) ranked 45 / 3000 candidates, Internal Medicine. October 1984 to June 1990: Medical school, University of Poitiers, France PARTICIPANTES PARTICIPANTS Dr. Lawrence Fong USCF Medical Centre, San Francisco, USA Lawrence Fong, M.D., is a Professor of Medicine in the Division of Hematology/Oncology at the University of California, San Francisco. He is focused on developing immune-based therapies for cancers including prostate, kidney, melanoma, and colorectal cancers. He has been involved in pre-clinical and clinical studies with sipuleucel-T and anti-CTLA4 antibodies. Dr. Fong currently leads a translational immunotherapy program at UCSF and also leads a research lab studying antigen-specific recognition of tumors in both mouse models and in patients. Current work includes developing biomarkers that are associated with clinical responses or side effects. Dr. Fong obtained his MD at Stanford, completed internal medicine training at University of Washington, and oncology fellowship at Stanford. He currently serves on multiple NIH study sections and committees including the NCI Investigational Drug Steering Committee (IDSC), and NCI Genitourinary Cancers Steering Committee (GUSC). He has served on the editorial board of the Journal of Clinical Oncology and currently serves as a senior editor for Cancer Immunology Research, a new journal from AACR. Dr. Jesús García-Donas Centro Integral Oncológico Clara Campal (CIOCC), Madrid. Head of the Gynecological, Genitourinary and Skin Cancer Unit. Director of the Familiar Cancer and Rare Tumors Program Jesús García-Donas was born in Alcalá de Guadaira (Sevilla) in 1974. He received his MD from the Universidad Complutense de Madrid in 1998 and subsequently trained as Medical Oncologist at the Hospital Universitario Clínico San Carlos, Madrid. After completing his oncology training in 2002, Jesús worked first in the Hospital Universitario de Elche. In 2003 later Jesús joined the Oncology Department of the Hospital Universitario Fundación Alcorcón, focusing in hereditary cancer syndromes and gynecological, genitourinary tumors. In 2009, he completed his sub-specialization in Genitourinary Tumors with a clinical fellowship at the New York Langone Medical Center under the supervision of Dr. Ana Ferrari. Since May 2012 Jesús leads the Gynecological, Genitourinary and Skin Cancer Unit and the Familiar and Rare Tumors Program at the Centro Integral Oncológico Clara Campal (Madrid). Jesús has participated as co-investigator in up to 210 Phase I, II and III clinical trials and has published over 20 papers in peer-reviewed journals, including the prestigious The Lancet Oncology and Journal of Clinical Oncology. Jesús currently leads several translational projects and clinical trials in the field of Kidney Cancer and Rare Tumors. Most relevant are the EuroTarget study funded by the 7th Framework Program of the European Union, that will deeply improve our knowledge of predictive biomarkers in renal tumors, the CIRClEs study (Circulating Endothelial Cells in renal cancer) and the phase II study of dovitnib, a new tyrosin kinase inhibitor, in adrenocortical carcinomas. Jesús has also received several grants and awards including the 2006 FREMAP award for investigational projects, the “Fundación Renal Iñigo Álvarez de Toledo” award, a grant for Independent Clinical Investigation from the Health Spanish Ministry (EC11-178) and a grant from the Instituto de Salud Carlos III within the Acción Estratégica en Salud program. PARTICIPANTES PARTICIPANTS Dr. Roberto García Figueiras Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela Main Research Field -Oncologic Imaging -Abdominal/Pelvic Radiology PhD in the field of FUNCTIONAL AND MOLECULAR IMAGING applied to Oncology (2014): “Valor de las técnicas de imagen funcional y molecular en los tumores” (“The Value of Functional and Molecular Imaging in Tumors”). Qualification: CUM LAUDE - 6 books chapters published devoted to oncologic imaging - 17 papers published devoted to oncologic imaging + other 34 radiological papers - Speaker in many meetings mainly focused on oncologic imaging - 12 national and international prizes in main radiological meetings - International Meetings: 64 posters presented - National Meetings: 53 posters presented Dra. Aránzazu González del Alba Hospital Universitari Son Espases, Palma de Mallorca Dr. Aránzazu González del Alba Baamonde holds a Degree in Medicine and Surgery from Madrid Autonomous University (1993). She completed her training in Clinical Oncology in Son Dureta University Hospital (Palma de Mallorca, 1994-1997) and holds a Master in Molecular Oncology: Molecular bases of Cancer. Molecular Pathology Program of the National Oncological Research Centre (CNIO), recognized by the European School of Oncology (2007-2009). She is a staff physician of the Department of Clinical Oncology of Son Espases Universitary Hospital and since 2002 she has directed the Unit of Urological and Gynecological tumors. Since 2009 she forms part of the Steering Committee of the Spanish Oncology Genitourinary Group (SOGUG), coordinating the Teaching Commission. PARTICIPANTES PARTICIPANTS Dr. Viktor Grünwald Hannover Medical School, Hannover, Germany Dr. Viktor Grünwald is Professor for Oncology at the Medical School Hannover. Dr. Grünwald received his medical degree from the Medical School Hannover in Hannover, Germany and completed his doctorial and professorial thesis on topics of genitourinary cancers. He chairs the tumor division of the center of rare disease at the Medical School Hannover. He is an author on more than 100 scientific articles, abstracts and oncology book chapters. Dr. Grünwald reviewes for several oncology journals. Dr. Grünwald is an active member of the European Organisation for Research and Treatment of Cancer (EORTC), American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO). He is board member of the German Medical Oncology studies group (AIO) and of the Central European Society for Anticancer drug Research (CESAR). He chairs the sarcoma group of the AIO and co-chairs the phase III unit of CESAR. Dr. Grünwald is a member of the Scientific Committee of the ESMO (non-prostate genitourinary committee), and for the German Society of Hematology and Oncology (DGHO). He acts as a faculty member at the Flims Workshop on Methods in Clinical Research and the International and European Kidney Cancer Symposium (I-KCS). Dr. Grünwald’s main focus is the development of novel anticancer therapeutics, with a particular interest on kidney cancer, sarcomas, and head and neck carcinomas. He participated in more than 70 clinical trials. Dr. Primo N. Lara UC Davis Comprehensive Cancer Center, Sacramento, USA Dr. Lara is a clinician-scientist whose principal research interests are in the field of developmental therapeutics, particularly in genitourinary and thoracic malignancies, as well as in cancer biomarker development. He has a national and international reputation in clinical-translational research and has chaired or co-chaired many cancer clinical trials from phase I to III. He directs an active clinical practice in genitourinary and thoracic malignancies and is a strong advocate for cancer clinical trials. Dr. Lara has received research funding from the National Institutes for Health/National Cancer Institute (including R01 and R21 awards) and the American Cancer Society, among others. He has authored or co-authored nearly 200 peer-reviewed manuscripts, most notably on novel or emerging anti-neoplastic strategies. He is currently principal investigator of the NCI-funded K12 Paul Calabresi Clinical Oncology Training Grant, the NCI-funded N01 Early Therapeutics Award, and the UC Davis ACS Institutional Research Grant. He also serves as an active co-investigator in several NCI-funded drug development awards at UC Davis. Dr. Lara is active in medical education and training, having served as chair of the American Society of Clinical Oncology’s Continuing Medical Education Subcommittee in 2012-2013 and Education Committee chair of the International Association for the Study of Lung Cancer from 2011-2013. He has chaired SWOG’s Advanced Kidney Cancer Organ Site since 2002, and serves as chair of SWOG’s Professional Review Committee. PARTICIPANTES PARTICIPANTS Dra. Anja Lorch, MD UKD Universitätsklinikum, Düsseldorf, Germany Education and Career 1991-1993 Training as radiographer, University hospital Tübingen 1993-1994 Department of Radiooncology University hospital Tübingen 1994-2000 Medical school, Philipps-University, Marburg Medical clerkship in Chicago (Northwestern University, USA) 2000-2002 Residency (AIP), department for hematology/oncology/immunology, (director: Prof. Dr. A. Neubauer), University hospital, Marburg 2002-2007 Fellowship (Assistenzärztin), department for hematology, oncology and immunology, (director: Prof. Dr. A. Neubauer), University hospital, Marburg 2006 Conferral of a doctorate Philipps-University Marburg 2007 Consultant for internal medicine (Fachärztin für Innere Medizin) 2008 Consultant for hematology/oncology (Fachärztin für Hämatologie und Onkologie) 2008 ESMO exam (European Society for Medical Oncology) 2008 “Professor Dr. Adolph Schmidtmann-Stiftung” grant for an observership at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, USA (09-11/2008), Department for urooncology Since 2009 Attendant (Oberärztin), Department for hematology, oncology and immunology, Philipps-University, Marburg (director: Prof. Dr. A. Neubauer) May 2011 Habilitation and junior professor, Philipps-University Marburg. Theme: “Prognose und Therapie rezidivierter Keimzelltumoren: Stellenwert der Hochdosischemotherapie“ 2011 Observership at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, USA (09-11/2011), Department for urooncology Since March 2012 Professor of Medical Oncology, Genitourinary Medical Oncology, Heinrich-Heine University, Düsseldorf Awards 2007 Wilsede Academy for Hematology and Oncology, “Hans-Jochen Illiger Gedächtnispreis 2007” (10 000 Euro) Membership in Scientific Communities Deutsche Gesellschaft für Hämatologie und Onkologie e.V. (DGHO). European Society for Medical Oncology (ESMO). American Society of Clinical Oncology (ASCO). Interdisziplinäre AG Hodentumoren. AG Urogenitaltumoren. Interdisziplinärer Arbeitskreis Uro-Onkologie Marburg e.V. PARTICIPANTES PARTICIPANTS Dr. Pablo Maroto Rey Hospital de la Santa Creu i Sant Pau, Barcelona Dr. Maroto is a medical oncologist working in the Sant Pau Hospital of Barcelona, Spain since 1999. From his position, Dr. Maroto has been actively working in the uro-oncology arena participating in more than 30 international clinical trials as principal investigator. He is member of different collaborative groups, among them the Spanish Oncology Genito-Urinary Group (SOGUG) where he has collaborated in the elaboration of Spanish Guidelines for the management of prostate, kidney and bladder cancer. Besides, he presently is the Chairman of the Germ Cell Cancer Group, the Spanish collaborative group for the treatment of Germ Cell cancer. Dra. Begoña Mellado González Hospital Clínic, Barcelona Begoña Mellado González is a Consultant Medical Oncologist and co-Chair of the Urology Cancer Unit at the Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. She graduated in Medicine from the University of Barcelona in 1989, completed her specialist training in Medical Oncology at the Hospital Clínic i Provincial de Barcelona in 1993 and was awarded her PhD by the University of Barcelona in 2002. She has also held research fellowship positions at the Hospital Clínic i Provincial de Barcelona (1990–1994) and the Memorial Sloan-Kettering Cancer Center (1995-1996). Dr. Mellado is the elected Leader of the Prostate Cancer Group at the Translational Oncology Research Laboratory, IDIBAPS, Hospital Clínic, University of Barcelona, and an active member of the Prostate Cancer Group at the Spanish Genitourinary Oncology Group (SOGUG). Her research focuses on urological cancer and translational research, particularly the detection and characterization of circulating tumor cells in prostate cancer, and molecular mechanisms of resistance to chemotherapy in castrate-resistant prostate cancer. She has authored or coauthored more than 50 peer-reviewed articles in these fields. PARTICIPANTES PARTICIPANTS Dra. Mª José Méndez-Vidal Hospital Universitario Reina Sofía, Córdoba Dr. Méndez-Vidal is Associate Professor at Cordoba University and an active member of the Spanish Oncology Genitourinary Group (SOGUG) and the Spanish Society of Medical Oncology. Dr. Méndez-Vidal received her M.D. degree from the Universidad of Málaga. She performed the Medical Oncology Residency at Clinical University Hospital in Córdoba, Spain. She joined the staff at the Medical Oncology Service of University Hospital in Córdoba and she is the Responsible of the Uro-oncological Unit. Her research interests are in Clinical GU Oncology, with special attention to prostate and renal cancer. Dr. Álvaro Montesa Hospital Universitario Carlos Haya, Málaga Licenciado en Medicina y Cirugía por la Universidad de Málaga en el año 2000 realizó la residencia en Oncología Médica en el Hospital Carlos Haya de Málaga. Tras su paso por los hospitales de Puerto Real de Cádiz y Virgen de las Nieves de Granada y una estancia externa como observador en el Memorial Sloan Kettering Cancer Center, retornó al Hospital Carlos Haya donde ejerce como adjunto especialista en el área de tumores genitourinarios desde el año 2007, participando como investigador principal en varios ensayos clínicos. PARTICIPANTES PARTICIPANTS Dr. José Luis Pérez Gracia Clínica Universitaria de Navarra, Pamplona Especialista del Departamento de Oncología de la Clínica Universidad de Navarra. Profesor titular de Medicina de la Universidad de Navarra, acreditado por la ANECA. Vocal de la Junta Directiva del Grupo Español de Investigación en Tumores Urológicos (SOGUG). Investigador principal en más de 60 ensayos clínicos y en 6 proyectos financiados en convocatorias competitivas. Co-autor de más de 60 publicaciones indexadas y de 12 capítulos de libro Revisor de 10 revistas especializadas. Miembro del Comité Editorial de PlosOne. Dr. Álvaro Pinto Hospital Universitario La Paz, – IdiPAZ, Madrid - Licenciado en Medicina y Cirugía por la Universidad de Valladolid (2002) -Médico Interno Residente de Oncología Médica en el Hospital Universitario La Paz, Madrid (2003-2007) -Médico Adjunto del Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid (2007 – actualidad). Responsable de la atención a pacientes con tumores urológicos - Doctor en Medicina por la Universidad Autónoma de Madrid, calificado sobresaliente Cum Laude (2009) -Investigador del Instituto de Investigación del Hospital La Paz (IdiPAZ), dentro del grupo de Oncología Traslacional - Miembro de las siguientes sociedades científicas: ASCO, ESMO, SEOM, SOGUG, Grupo Germinal - Miembro del Grupo de Trabajo de Prevención del Cáncer y Diagnóstico Precoz de la SEOM - Participación como investigador principal o investigador colaborador en más de 40 ensayos clínicos -Autor de artículos publicados en revistas de alto impacto del campo de la oncología (Journal of Clinical Oncology, Cancer Treatment Reviews, European Journal of Cancer, Cancer and Metastasis Reviews, Urologic Oncology, etc.) - Autor de 16 capítulos en libros dentro del campo de la oncología -Presentación de comunicaciones en congresos nacionales e internacionales (ASCO Annual Meeting, ESMO Annual Meeting. ASCO Genitourinary Cancer Symposium, etc.) PARTICIPANTES PARTICIPANTS Dr. Thomas Powles Barts Cancer Institute, London, UK Prof. Powles is the lead for Solid Tumors at Barts Cancer Institute. He leads a Translational Oncology Group and is the Chief Investigator for 10 national and international studies. He has written over 100 publications in the field of GU cancer and is on the faculty of a number of international meetings including ESMO GU ASCO and ASCO in 2013. Dr. Javier Puente Hospital Clínico Universitario San Carlos, Madrid Javier Puente es oncólogo médico en el Hospital Clínico San Carlos de Madrid, siendo uno de los responsables de la Unidad de Tumores torácicos, urológicos y melanoma. Su labor asistencial se acompaña de una intensa actividad investigadora (como miembro del Grupo Español de tumores genitourinarios (SOGUG) y del Grupo Español de Cáncer de Pulmón (GECP), así como docente, siendo Profesor Asociado de Medicina en la Universidad Complutense de Madrid. Es además Asesor Técnico Nacional de la Asociación Española contra el Cáncer (AECC). El Dr. Puente ha colaborado como autor en más de 50 artículos en revistas internacionales, y ha sido nombrado recientemente Secretario Científico de la Sociedad Española de Oncología Médica (SEOM). PARTICIPANTES PARTICIPANTS Dr. Juan Fco. Rodríguez-Moreno Hospital Madrid Norte Sanchinarro, Madrid Dr. Rodríguez is medical oncologist in the Department of Genitourinary & Gynecological tumors and Coordinator of the Department of Skin Cancer of the Centro Integral Oncológico Clara Campal (Comprehensive Cancer Center), Madrid (Spain). He participates as Clinical collaborator in the Prostate Cancer and Genitourinary Tumours Clinical Research Unit of the Spanish National Cancer Research Center (CNIO). Dr. Rodríguez is also Associate Professor at the University CEU San Pablo and member of the Teaching Committee of SOGUG. Dr. Francisco Zambrana Hospital Infanta Sofía, Madrid University of Seville Medical School. Clinical Fellowship in Medical Oncology (Hospital Universitario Virgen Macarena, Seville. 2009). MPhil in tumor pathology (University of Seville, 2006). Observership program at MD Anderson Cancer Center (Breast and Lymphoma Departments, 2008) and University Hospital (Palliative Medicine, University of Navarra, 2006). MPhil in Oncology Research (Universidad San Pablo CEU & CIOCC, 2012). Observership program at Hellen Diller Family Comprehensive Cancer Center (Genitourinary Center, 2014). Ongoing clinical research in metabolomics (volatile organic compounds) and genomics for prediction of response to chemoradiation. Areas of interest: cancer immunotherapy, GU, lung and head & neck Oncology. PARTICIPANTES PARTICIPANTS V SIMPOSIO CIENTÍFICO SOGUG 5th SCIENTIFIC MEETING SOGUG Madrid 19 al 21 de Noviembre 2014 | 19th to 21st November 2014 Organizado por | Organized by Sede | Venue Casino de Madrid - C/ Alcalá, 15, Madrid - Telf.: 91 521 87 00 *Para acceder al Casino de Madrid es imprescindible el uso de chaqueta y corbata | Jacket and tie are required to access the conference venue Organizado por | Organized by www. simposiocientificosogug.net Patrocinadores | Sponsors Colaboradores | Collaborators Con el auspicio de | Under auspices of 18, cat. 1 ESMO-MORA points Solicitada acreditación a la Comisión de Formación Continuada de las Profesiones Sanitarias de la Comunidad de Madrid | Accreditation by the Spanish System of Continuing Medical Education requested Technical Secretariat TACTICS MD - T. 93 451 17 24 - [email protected]